Abstract
How effectively and quickly endothelial caveolae can transcytose in vivo is unknown, yet critical for understanding their function and potential clinical utility. Here we use quantitative proteomics to identify aminopeptidase P (APP) concentrated in caveolae of lung endothelium. Electron microscopy confirms this and shows that APP antibody targets nanoparticles to caveolae. Dynamic intravital fluorescence microscopy reveals that targeted caveolae operate effectively as pumps, moving antibody within seconds from blood across endothelium into lung tissue, even against a concentration gradient. This active transcytosis requires normal caveolin-1 expression. Whole body γ-scintigraphic imaging shows rapid, specific delivery into lung well beyond that achieved by standard vascular targeting. This caveolar trafficking in vivo may underscore a key physiological mechanism for selective transvascular exchange and may provide an enhanced delivery system for imaging agents, drugs, gene-therapy vectors and nanomedicines. 'In vivo proteomic imaging' as described here integrates organellar proteomics with multiple imaging techniques to identify an accessible target space that includes the transvascular pumping space of the caveola.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Schnitzer, J.E., Oh, P. & McIntosh, D.P. Role of GTP hydrolysis in fission of caveolae directly from plasma membranes. Science [publisher's erratum appears in Science 1996 Nov 15;274(5290):1069] 274, 239–242 (1996).
Oh, P., McIntosh, D.P. & Schnitzer, J.E. Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. J. Cell Biol. 141, 101–114 (1998).
Razani, B. et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276, 38121–38138 (2001).
Drab, M. et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293, 2449–2452 (2001).
Durr, E. et al. Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat. Biotechnol. 22, 985–992 (2004).
Oh, P. et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429, 629–635 (2004).
Schnitzer, J.E., Carley, W.W. & Palade, G.E. Specific albumin binding to microvascular endothelium in culture. Am. J. Physiol. 254, H425–H437 (1988).
Parton, R.G. Ultrastructural localization of gangliosides; GM1 is concentrated in caveolae. J. Histochem. Cytochem. 42, 155–166 (1994).
Pelkmans, L., Kartenback, J. & Helenius, A. Caveolar endocytosis of Simian virus 40 reveals a novel two-step vesicular transport pathway to the ER. Nat. Cell Biol. 3, 473–483 (2001).
Schnitzer, J.E., Oh, P., Pinney, E. & Allard, J. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J. Cell Biol. 127, 1217–1232 (1994).
Thomsen, P., Roepstorff, K., Stahlhut, M. & van Deurs, B. Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol. Biol. Cell 13, 238–250 (2002).
Severs, N.J. Caveolae: static inpocketings of the plasma membrane, dynamic vesicles or plain artifact? J. Cell Sci. 90, 341–348 (1988).
Bundgaard, M., Frokjaer-Jensen, J. & Crone, C. Endothelial plasmalemmal vesicles as elements in a system of branching invaginations from the cell surface. Proc. Natl. Acad. Sci. USA 76, 6439–6442 (1979).
McIntosh, D.P., Tan, X.-Y., Oh, P. & Schnitzer, J.E. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: A pathway to overcome cell barriers to drug and gene delivery. Proc. Natl. Acad. Sci. USA 99, 1996–2001 (2002).
Simionescu, M., Simionescu, N. & Palade, G.E. Morphometric data on the endothelium of blood capillaries. J. Cell Biol. 60, 128–152 (1974).
Simionescu, M. & Simionescu, N. Endothelial transport of macromolecules: transcytosis and endocytosis. A look from cell biology. Cell Biol. Rev. 25, 1–78 (1991).
Carver, L.A. & Schnitzer, J.E. Caveolae: mining little caves for new cancer targets. Nat. Rev. Cancer 3, 571–581 (2003).
Schnitzer, J.E. Update on the cellular and molecular basis of capillary permeability. Trends Cardiovasc. Med. 3, 124–130 (1993).
Jain, R.K. The next frontier of molecular medicine: delivery of therapeutics. Nat. Med. 4, 655–657 (1998).
Herschman, H.R. Molecular imaging: looking at problems, seeing solutions. Science 302, 605–608 (2003).
Rudin, M. & Weissleder, R. Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2, 123–131 (2003).
Tomlinson, E. Theory and practice of site-specific drug delivery. Adv. Drug Deliv. Rev. 1, 87–198 (1987).
Dvorak, H.F., Nagy, J.A. & Dvorak, A.M. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 3, 77–85 (1991).
Schnitzer, J.E. Vascular targeting as a strategy for cancer therapy. N. Engl. J. Med. 339, 472–474 (1998).
Jenkins, R.G., McAnulty, R.J., Hart, S.L. & Laurent, G.J. Pulmonary gene therapy. Realistic hope for the future, or false dawn in the promised land? Monaldi Arch. Chest Dis. 59, 17–24 (2003).
Courrier, H.M., Butz, N. & Vandamme, T.F. Pulmonary drug delivery systems: recent developments and prospects. Crit. Rev. Ther. Drug Carrier Syst. 19, 425–498 (2002).
Kozower, B.D. et al. Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat. Biotechnol. 21, 392–398 (2003).
Burrows, F.J. & Thorpe, P.E. Vascular targeting–a new approach to the therapy of solid tumors. Pharmacol. Ther. 64, 155–174 (1994).
Schnitzer, J.E. Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo. Adv. Drug Deliv. Rev. 49, 265–280 (2001).
Carver, L.A. & Schnitzer, J.E. Tissue-specific pharmacodelivery and overcoming key cell barriers in vivo: Vascular targeting of caveolae. in Biomedical Aspects of Drug Targeting (eds. Muzykantov, V. & Torchilin, B.) 107–128, (Kluwer Academic Publishers, Boston, 2002).
Denekamp, J. Vasculature as a target for tumour therapy. Progr. Appli. Microcirc. 4, 28–38 (1984).
Schnitzer, J.E. The endothelial cell surface and caveolae in health and disease. in Vascular Endothelium: Physiology, Pathology, and Therapeutic Opportunities (ed. Born, G., Shwartz, CJ) 77–95, (Schattauer, Stuttgart, 1997).
Carver, L.A. & Schnitzer, J.E. Proteomic mapping of endothelium and vascular targeting in vivo, in Endothelial Biomedicine (ed. Aird, W.) 881–897, ((In press) 2007).
Pasqualini, R. & Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 380, 364–366 (1996).
Muzykantov, V.R. et al. Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Proc. Natl. Acad. Sci. USA 96, 2379–2384 (1999).
Hughes, B.J., Kennel, S.K., Lee, R. & Huang, L. Monoclonal antibody targeting of liposomes to mouse lung in vivo. Cancer Res. 49, 6214–6220 (1989).
Schnitzer, J.E., McIntosh, D.P., Dvorak, A.M., Liu, J. & Oh, P. Separation of caveolae from associated microdomains of GPI-anchored proteins. Science 269, 1435–1439 (1995).
Oh, P. & Schnitzer, J.E. Isolation and subfractionation of plasma membranes to purify caveolae separately from glycosyl-phospatidylinositol-anchored protein microdomains. in Cell Biology: A laboratory handbook (ed. Celis, J.) 34–46, (Academic Press, 1998).
Oh, P. & Schnitzer, J.E. Immunoisolation of caveolae with high affinity antibody binding to the oligomeric caveolin cage: toward understanding the basis of purification. J. Biol. Chem. 274, 23144–23154 (1999).
Muro, H., Shirasawa, H., Maeda, M. & Nakamura, S. Fc receptors of liver sinusoidal endothelium in normal rats and humans. A histology study with soluble immune complexes. Gastroenterology 93, 1078–1085 (1987).
Russell, J. et al. Iodination of annexin V for imaging apoptosis. J. Nucl. Med. 43, 671–677 (2002).
Chaurand, P., Sanders, M.E., Jensen, R.A. & Caprioli, R.M. Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am. J. Pathol. 165, 1057–1068 (2004).
Nichols, B.J. et al. Rapid cycling of lipid raft markers between the cell surface and Golgi complex. J. Cell Biol. 153, 529–541 (2001).
Porter, G.A. & Bankston, P.W. Maturation of myocardial capillaries in the fetal and neonatal rat: an ultrastructural study with a morphometric analysis of the vesicle populations. Am. J. Anat. 178, 116–125 (1987).
Schnitzer, J.E., Liu, J. & Oh, P. Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, and GTPases. J. Biol. Chem. 270, 14399–143404 (1995).
McIntosh, D.P., Oh, P. & Schnitzer, J.E. Caveolae require intact VAMP-2 for targeted transport in vascular endothelium. Am. J. Physiol. 277, H2222–H2232 (1999).
Miller, N. & Vile, R. Targeted vectors for gene therapy. FASEB J. 9, 190–199 (1995).
Galanis, E., Vile, R. & Russell, S.J. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit. Rev. Oncol. Hematol. 38, 177–192 (2001).
Bilbao, G., Gomez-Navarro, J. & Curiel, D.T. Targeted adenoviral vectors for cancer gene therapy. Adv. Exp. Med. Biol. 451, 365–374 (1998).
Lehr, H.A., Leunig, M., Menger, M.D., Nolte, D. & Messmer, K. Dorsal skinfold chamber technique for intravital microscopy in nude mice. Am. J. Pathol. 143, 1055–1062 (1993).
Alger, G.H. An adaptation of the transparent chamber technique to the mouse. J. Natl. Cancer Inst. 4, 1–11 (1943).
Frost, G.I. & Borgstrom, P. Real time in vivo quantitation of tumor angiogenesis. Methods Mol. Med. 85, 65–78 (2003).
Frost, G.I. et al. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration. Microvasc. Res. 69, 1–9 (2005).
Moffat, J. et al. A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen. Cell 124, 1283–1298 (2006).
McElroy, D. et al. Performance evaluation of A-SPECT: A high resolution desktop pinhole SPECT system for imaging small animals. IEEE Trans. Nucl. Sci. NS 49, 2139–2147 (2002).
Acknowledgements
We thank Alexina Wempren, Michelle Bourne, Lisa Pang, Dale Winger and Traci Smith for technical assistance. This research was supported by funds provided in part by National Institutes of Health grants R01 HL52766, R01 HL58216, R01 HL074063, R24CA95893 and PO1CA104898 and by the Tobacco-Related Disease Research Program, grant number 11RT-0167.
Author information
Authors and Affiliations
Contributions
P.O., Figures 1a,c, 2, 3, 4, 6, Supplementary Figures 2b,c, 3b–d, 4, 5, subcellular fractionation, immunoblotting, lentiviral gene silencing siRNA, animal surgical procedures, intravital microscopy imaging and analysis, fluorophore and 125I labeling of proteins, A-SPECT and X-SPECT imaging, Supplementary Videos 1,2,3,4,5,6; P.B., Figures 2, 3, 4, 5, intravital microscopy and analysis, Supplementary Videos 1, 2; H.W., Figure 1b,c, all electron microscopy imaging and analysis; Y.L., Supplementary Figures 1 and 2a, mass spectrometry (MS) and analysis of MS data; B.J.B., Figures 4, 5, intravital microscopy image processing, custom MatLab scripting; A.C., Figure 7a–c, X-SPECT imaging, radiolabeling, Supplementary Figure 5; K.I., Figure 6a,b,j,k,m, Supplementary Videos 3,4,5,6; K.R.Z., Figure 7d–f; R.B., Figure 1c, gold particle preparation; J.E.T., Figure 1a, Supplementary Figures 3a,b and 5, monoclonal antibody production, screening and characterization; J.E.S., manuscript, experiment design and result analysis.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Figure 1
MS/MS spectra of peptides and sequence coverage for rat caveolin-1 and APP found concentrated in isolated caveolae. (PDF 1404 kb)
Supplementary Figure 2
Rat APP protein sequence and TX3.833 staining of cells induced to express APP. (PDF 301 kb)
Supplementary Figure 3
Antibody specificity and antigen expression analysis. (PDF 185 kb)
Supplementary Figure 4
Assessment of caveolin-1 knockdown in rat tissue. (PDF 170 kb)
Supplementary Figure 5
Lung targeting indices from in vivo biodistribution analysis of mAPP. (PDF 172 kb)
Supplementary Figure 6
Segmental expression of APP in lung vasculature. (PDF 127 kb)
Supplementary Table 1
Peptides identified by mass spectrometry for rat caveolin-1 and APP. (PDF 22 kb)
Supplementary Video 1
Live imaging by fluorescence intravital microscopy of mAPP lung accumulation, including endothelial targeting and processing. Athymic nude mice with organ tissue implanted in dorsal skin window chambers were injected via the tail vein with mAPP conjugated to fluorophore Alexa A488 (mAPP-A488). (See Experimental Procedures, and low magnification phase imaging of the lung tissue (yellow outline) implanted in surrounding skin. Note the more extensive vasculature in the lung tissue versus the skin. Imaging of fluorescence detected in lung but not skin tissue followed by higher magnification of fluorescence detected at 60 seconds, showing the yellow circled region in Figure 2E. (MOV 7579 kb)
Supplementary Video 2
Continuous dynamic live imaging of solitary blood microvessel by intravital microscopy. Athymic nude mouse with implanted lung tissue was injected via the tail vein with 30μg mIgG-A568 (mIgG-TR, control antibody) followed 1 minute later with 3μg mAPP-A488 (TX3.833-A488, caveolae targeting antibody). Black and white imaging shows phase contrast image of vessel, without other vessels nearby. Fluorescence imaging is shown from injection of mAPP at 1 min after injection of mIgG-A568. (Time stamp 00:00:59 – 00:02:00) Close-up fluorescence imaging after low dose injection mAPP-A488 (green). Note that the 10-fold lower dose of caveolae targeting antibody produces minimal intravessel signal, yet clear, progressively concentrated signal first at the endothelial cell surface and then within the perivascular space inside the tissue. (Time stamp 00:02:01 – 00:02:10) Close up fluorescence imaging of same vessel, 2 min after injection of mIgG-A568 (red), showing ample intravessel signal but no detectable extravasation. (Time stamp 00:02:11 – 00:02:15) Combined red/green fluorescence imaging shows red signal from mIgG-A568 remaining inside vessel, but green mAPP-A488 signal (at 1:11 to 1:15 min after injection) persisting at the vessel wall and accumulating in the perivascular space inside the tissue. (MOV 10552 kb)
Supplementary Video 3
Video imaging of rapid initial phase of lung uptake of 125I-mAPP. Rats were imaged continuously for 1 min immediately after tail vein injection of 125I-mAPP (A) or 125I-mIgG (B) as described in Figure 6A and B. Images were collected at 1 second intervals then placed to run consecutively 6 times faster than real time (1 min compressed to 10 seconds). Note the heart position (arrowhead) which is devoid of radiolabeled mAPP. (MOV 1081 kb)
Supplementary Video 4
SPECT imaging of APP immunotargeting in vivo at 30 minutes. SPECT images of rats injected I.V. (tail vein) with 125I-mAPP were captured 30 minutes post-injection using a parallel plate collimator (top panel) or pinhole collimator (bottom panel). Images were collected every 6° for 30 sec per frame, then placed to run consecutively to make the video. Animal is oriented with head toward the bottom of the frame. (MOV 1083 kb)
Supplementary Video 5
Surface rendering of SPECT imaging of APP immunotargeting in vivo at 30 minutes. SPECT imaging data from the bottom panel of Supplementary Video 4 was used to create a surface rendered image of lungs. SPECT images of rats injected I.V. (tail vein) with 125I-mAPP were captured 30 minutes post-injection using pinhole collimator. Images were collected every 6° for 30 sec per frame, then placed to run consecutively to make the video. (Left panel) Axis of rotation is longitudinal (along the y-axis), rotation occurs in the y-plane as depicted in Supplementary Video 4, and the animal is oriented with the head toward the bottom of the frame. (Right panel) Axis of rotation is horizontal (along the x-axis), and rotation of the image occurs in the z-plane. (MOV 4984 kb)
Supplementary Video 6
SPECT imaging of APP immunotargeting in vivo at 48 hours. SPECT images of rats (same rats shown in Supplementary Video 4 and 5) injected I.V. at the tail vein with 125I-mAPP were captured 48 hours post-injection using a pinhole collimator. Images were collected every 6° for 30 sec per frame, then placed to run consecutively to make the video. Signal from thyroid is visible at the top of the frame. Animal is oriented with head toward the top of the frame. (MOV 406 kb)
Rights and permissions
About this article
Cite this article
Oh, P., Borgström, P., Witkiewicz, H. et al. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol 25, 327–337 (2007). https://doi.org/10.1038/nbt1292
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1292
This article is cited by
-
Mfsd2a attenuated hypoxic-ischemic brain damage via protection of the blood–brain barrier in mfat-1 transgenic mice
Cellular and Molecular Life Sciences (2023)
-
The spectrin cytoskeleton integrates endothelial mechanoresponses
Nature Cell Biology (2022)
-
Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy
BMC Cancer (2021)
-
Investigating receptor-mediated antibody transcytosis using blood–brain barrier organoid arrays
Fluids and Barriers of the CNS (2021)
-
Overcoming the blood–brain barrier by Annexin A1-binding peptide to target brain tumours
British Journal of Cancer (2020)